Among over 500 obese patients with OSAS, long-term tirzepatide treatment led to significant reductions in body weight, AHI, and oxygen desaturation index, with particularly pronounced benefits in patients with concurrent glucose and lipid metabolism abnormalities (52)
We report herein a series of pharmacological and molecular studies in two validated mouse models of PCOS, generated by gestational (PNA) or postweaning (PWA) androgenization, addressing the effects of GLP1-based multi-agonist therapies on metabolic and reproductive traits of PCOS
Developed by Novo Nordisk, amycretin is a novel, long-acting, unimolecular agonist targeting both GLP-1 and amylin receptors, designed for both oral and subcutaneous administration
2012;34(10):12817 Veringa SJE, Nanayakkara PWB, van Ittersum FJ
Riboflavin production by Aspergillus terreus from beet-molasses